Our Approach

Collaboration propels innovation

At Ichnos Glenmark Innovation, we believe in the power of collaboration to drive innovation. Being an alliance between Ichnos and Glenmark, we ourselves embody this belief.

Collaboration that helps us combine forces of expertise, technology, speed and reach between Ichnos and Glenmark as well as among other stakeholders.

Collaboration that helps us transform the world of oncology by creating novel cutting-edge therapeutics, faster.
Collaboration that kindles new hope for oncology patients, their families and healthcare professionals.

Our identity is a crisp and apt expression on our belief.

The letters IGI combine with a graphic of a compass to suggest how collaboration guides IGI towards innovation.

Our brand line ‘Collaboration propels innovation’ completes the message.

Approach

Our vision

Daring to imagine a world where cure is possible. Moving beyond hope, with therapies that will forever transform medicine and lives.

Approach

Our mission

To co-create innovative treatment solutions that make healthier living possible.

Cancer cure through collaboration

At Ichnos Glenmark Innovation, we strive to fast-track the development of new cancer cures through collaboration.

We focus on creating cutting-edge solutions to treat hematological malignancies and solid tumors through collaborations not only between Ichnos and Glenmark, but also with other institutions including but not limited to other biotech companies, start-ups, investors and academia.

We’re pioneering advancements in oncology that enhance the immune system’s ability to detect and kill cancer. Born from our patented BEAT® (Bispecific Engagement by Antibodies based on the T-cell receptor) technology platform, ISB 1442 (CD38 x CD47 biparatopic bispecific antibody) and ISB 2001 (BCMA x CD38 x CD3 trispecific antibody) are in development for patients with multiple myeloma and acute myeloid leukemia. HPK1 Inhibitor (GRC 54276), an orally administered IO-adjuvant treatment, is in development for patients with solid tumors.

This approach has potential to treat patients with multiple myeloma and acute myeloid leukemia, including those non-responsive or resistant to standard care.

Strategic priorities for biologics discovery research in oncology

Focus on disease-centric approach and leverage BEAT® antibody engineering platform to deliver first-in-class candidates.


Multiple Myeloma (MM):


Deliver a competitive MM portfolio by advancing next wave of T-cell engagers and innate immune engagers (e.g., NK, macrophages)


Hematological Malignancies:


Accelerate delivery of innovative concepts by leveraging tri-specific T-cell and innate immune engagers (e.g., NK, macrophages)


Solid Tumors:

  • Leverage BEAT® 2.0 in solid tumors
  • Further develop our HPK1 inhibitor
Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.
  1. Burugu, S., Dancsok, A. R. & Nielsen, T. O. Emerging targets in cancer immunotherapy. Semin Cancer Biol. 52:39-52 (2018).
  2. Ichnos Sciences’ ongoing clinical trial of ISB 1442 in relapsed refractory Multiple Myeloma. Available here. NLM identifier: NCT05427812


Multiple Myeloma (MM):

Deliver a competitive MM portfolio by advancing next wave of T-cell engagers and innate immune engagers (e.g., NK, macrophages)

Hematological Malignancies:

Accelerate delivery of innovative concepts by leveraging tri-specific T-cell and innate immune engagers (e.g., NK, macrophages)

Solid Tumors:
  • Leverage BEAT® 2.0 in solid tumors
  • Further develop our HPK1 inhibitor
Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.
  1. Burugu, S., Dancsok, A. R. & Nielsen, T. O. Emerging targets in cancer immunotherapy. Semin Cancer Biol. 52:39-52 (2018).
  2. Ichnos Sciences’ ongoing clinical trial of ISB 1442 in relapsed refractory Multiple Myeloma. Available here. NLM identifier: NCT05427812